BioCryst to Report Second Quarter 2025 Financial Results on August 4
BioCryst Pharmaceuticals (Nasdaq: BCRX) has scheduled its second quarter 2025 financial results announcement for Monday, August 4, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update.
Investors can access the live call by dialing 1-844-481-2942 (domestic) or 1-412-317-1866 (international). A live webcast and replay will be available in the investors section at www.biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per lunedì 4 agosto 2025. La società terrà una conference call e una webcast alle 8:30 a.m. ET per discutere i risultati finanziari e fornire un aggiornamento aziendale.
Gli investitori potranno partecipare alla chiamata in diretta chiamando il numero 1-844-481-2942 (nazionale) o 1-412-317-1866 (internazionale). Una webcast in diretta e la registrazione saranno disponibili nella sezione investitori su www.biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha programado el anuncio de resultados financieros del segundo trimestre de 2025 para el lunes 4 de agosto de 2025. La compañía realizará una llamada conferencia y una transmisión en vivo a las 8:30 a.m. ET para discutir los resultados financieros y ofrecer una actualización corporativa.
Los inversionistas pueden acceder a la llamada en vivo marcando al 1-844-481-2942 (nacional) o al 1-412-317-1866 (internacional). La transmisión en vivo y la repetición estarán disponibles en la sección de inversionistas en www.biocryst.com.
BioCryst Pharmaceuticals (나스닥: BCRX)는 2025년 2분기 재무 실적 발표를 2025년 8월 4일 월요일로 예정했습니다. 회사는 오전 8:30 ET에 컨퍼런스 콜과 웹캐스트를 진행하여 재무 실적과 회사 업데이트를 공유할 예정입니다.
투자자들은 국내 전화번호 1-844-481-2942 또는 국제 전화번호 1-412-317-1866로 라이브 콜에 참여할 수 있습니다. 라이브 웹캐스트와 재방송은 투자자 섹션의 www.biocryst.com에서 제공됩니다.
BioCryst Pharmaceuticals (Nasdaq : BCRX) a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le lundi 4 août 2025. La société organisera une conférence téléphonique et une webdiffusion à 8h30 ET pour discuter des résultats financiers et fournir une mise à jour d'entreprise.
Les investisseurs peuvent accéder à l'appel en direct en composant le 1-844-481-2942 (national) ou le 1-412-317-1866 (international). Une webdiffusion en direct et un replay seront disponibles dans la section investisseurs sur www.biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für Montag, den 4. August 2025 angesetzt. Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Finanzergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Investoren können den Live-Anruf unter der Nummer 1-844-481-2942 (national) oder 1-412-317-1866 (international) verfolgen. Ein Live-Webcast und eine Aufzeichnung sind im Investor-Bereich auf www.biocryst.com verfügbar.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2025 financial results on Monday, August 4, 2025.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
When will BioCryst (BCRX) report Q2 2025 earnings?
How can I access BioCryst's Q2 2025 earnings call?
Where can I find the replay of BioCryst's Q2 2025 earnings webcast?
What time is BioCryst's Q2 2025 earnings call?
